EUVIMEDEUVIMED entdecken
Beobachtungsstudie

The effect of biologic disease modifying anti-rheumatic drugs on the neutrophil–lymphocyte ratio in psoriatic arthritis patients

Martin Lauran, Chelsea Kyeremateng, Afrida Haque, Sara Rizal, Humairaa Ahmed, Samyak Pandey, Muhammad K Nisar

Clinical Rheumatology · 2026-07 · 45 (7) · 4277-4285

DOI: 10.1007/s10067-026-08233-5 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical Rheumatology, online erschienen am 19.06.2026. Verfasst von Martin Lauran und 6 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Department, Bedfordshire Hospitals NHS Foundation Trust, Dunstable University Hospital, Lewsey Rd, Luton, LU4 0DZ, UK. martinlauran123@h…. Hauptthemen laut MEDLINE: Arthritis, Psoriatic, Neutrophils, Lymphocytes, Antirheumatic Agents. Die Arbeit nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Cardiovascular mortality is up to 43% greater in patients with Psoriatic Arthritis (PsA) when compared to the general population. Whilst composite cardiovascular disease risk prognosticators exist, an emerging inexpensive biomarker known as the neutrophil-lymphocyte ratio (NLR) has been demonstrated to be a risk-associated biomarker of cardiovascular disease (CVD) in the general population. This study therefore aimed to assess the effect of biologic disease modifying antirheumatic drug (bDMARDs) on the NLR in a cohort of adult patients diagnosed with PsA. METHODS: A retrospective single-centre observational study was conducted using an electronic health record database including 183 adult patients diagnosed with PsA between 1983 and 2024. The NLR of patients was calculated pre- and post-initiation of bDMARDs and statistical significance was analysed using several different statistical analysis tools. RESULTS: The overall number of patients in the higher NLR risk stratification group (NLR > 2) was significantly reduced from 104 to 64 post-biologic initiation. Additionally, there was a statistically significant reduction of 24.0% in the average NLR of the entire patient cohort from 2.58 to 1.96 pre- and post-biologic initiation respectively. CONCLUSION: Our study demonstrates that over a third of patients had a significant NLR reduction post-biologic initiation. The mean NLR of the entire patient cohort demonstrated a shift to a lower CVD risk-associated stratified NLR group (NLR < 2), post-biologic treatment. BDMARD treatment in PsA patients therefore demonstrates a significant reduction in the NLR metric, with a varying degree of theoretical impact on the CVD risk reduction among different biologic drugs and classes. Key Points • bDMARDs reduce the Neutrophil-Lymphocyte Ratio in Psoriatic Arthritis patients. • Both TNF inhibitor and IL-17 inhibitors bDMARDs were associated with significant reductions in the Neutrophil-Lymphocyte Ratio in Psoriatic Arthritis patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, PsoriaticNeutrophilsLymphocytesAntirheumatic AgentsBiological ProductsHumansFemaleMaleMiddle AgedRetrospective StudiesAdultCardiovascular DiseasesAgedBiomarkers

Stichwörter der Autor:innen

BDMARDsCardiovascular disease biomarkerCsDMARDsNeutrophil–lymphocyte ratioPsoriatic arthritis

Substanzen

Antirheumatic AgentsBiological ProductsBiomarkers

Autor:innen und Institutionen

  • Rheumatology Department, Bedfordshire Hospitals NHS Foundation Trust, Dunstable University Hospital, Lewsey Rd, Luton, LU4 0DZ, UK. martinlauran123@hotmail.com.
  • Rheumatology Department, Bedfordshire Hospitals NHS Foundation Trust, Dunstable University Hospital, Lewsey Rd, Luton, LU4 0DZ, UK.

Zitieren

APA

Lauran, M., Kyeremateng, C., Haque, A., Rizal, S., Ahmed, H., Pandey, S., & Nisar, M. K. (2026). The effect of biologic disease modifying anti-rheumatic drugs on the neutrophil–lymphocyte ratio in psoriatic arthritis patients. Clinical Rheumatology, 45(7), 4277-4285. https://doi.org/10.1007/s10067-026-08233-5

Vancouver

Lauran M, Kyeremateng C, Haque A, Rizal S, Ahmed H, Pandey S, et al. The effect of biologic disease modifying anti-rheumatic drugs on the neutrophil–lymphocyte ratio in psoriatic arthritis patients. Clinical Rheumatology. 2026;45(7):4277-4285. doi:10.1007/s10067-026-08233-5

BibTeX
@article{Lauran2026,
  author = {Lauran, Martin and Kyeremateng, Chelsea and Haque, Afrida and Rizal, Sara and Ahmed, Humairaa and Pandey, Samyak and Nisar, Muhammad K},
  title = {The effect of biologic disease modifying anti-rheumatic drugs on the neutrophil–lymphocyte ratio in psoriatic arthritis patients},
  journal = {Clinical Rheumatology},
  year = {2026},
  volume = {45},
  number = {7},
  pages = {4277--4285},
  doi = {10.1007/s10067-026-08233-5}
}
Kostenlos starten →